Neurologix names Adrian Adams as Chairman, CEO
In his new role, Adams will be responsible for strengthening the company’s R&D operations and commercial infrastructures to support NLX-P101. Prior to joining Neurologix, Adams worked as the
Amgen has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for Repatha (evolocumab) supporting its broader use prior to a first heart attack or stroke.